SCHEMBL5891168

SCHEMBL5891168

COc1ccccc1-c1ccc(C(=O)N2Cc3ccc(C(=O)N(C)Cc4cccnc4)n3Cc3ccccc32)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 3/20 0.49
AVPR1A P37288 2/20 0.43
ROCK2 O75116 3/20 0.40
ROCK1 Q13464 1/20 0.40
PDK1 Q15118 5/20 0.39
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
PDK2 Q15119 2/20 0.36
PDK3 Q15120 2/20 0.36
PDK4 Q16654 2/20 0.36
CLK1 P49759 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5891244 0.95 AVPR2 (0.46) AVPR2AVPR1AROCK2ROCK1PDK1
SCHEMBL5891612 0.95 AVPR2 (0.46) AVPR2AVPR1AROCK2ROCK1PDK1
SCHEMBL5891697 0.94 AVPR2 (0.45) AVPR2AVPR1AROCK2ROCK1PDK1
SCHEMBL5891002 0.93 AVPR2 (0.44) AVPR2AVPR1AROCK2ROCK1PDK1
SCHEMBL5891434 0.92 AVPR2 (0.49) AVPR2AVPR1AROCK2ROCK1PDK1
SCHEMBL5891055 0.90 AVPR2 (0.47) AVPR2AVPR1AROCK2ROCK1PDK1
SCHEMBL5890712 0.86 AVPR2 (0.48) AVPR2AVPR1AROCK2ROCK1PDE4A
SCHEMBL5891209 0.86 ALDH1A1 (0.48) AVPR2ROCK2ROCK1
SCHEMBL5890737 0.85 AVPR1A (0.42) AVPR2AVPR1APDK1CLK1HSD17B2
SCHEMBL5786566 0.85 AVPR2 (0.54) AVPR2AVPR1AROCK2PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064120-B2 Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists WYETH (US) 2006-06-20 US claimed
WO-2002083683-A9 NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS WYETH CORP (US) 2004-02-26 WO claimed
US-20030055047-A1 Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists WYETH 2003-03-20 US claimed
US-7064120-B2 Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists WYETH (US) 2006-06-20 US disclosed
US-20030055047-A1 Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists WYETH 2003-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055047-A1 Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists OXTR, OPRL1, OPRK1 AVPR2 70/4885AVPR1A 33/4885ROCK2 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.